Successful discontinuation of eculizumab therapy in a patient with aHUS

Annals of Hematology

Volumn 93, Issue 8, 2014, Pages 1423-1425

  Pu, Jeffrey J ^a,b   Sido, Abigail ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB;

ACUTE KIDNEY FAILURE; AGED; CASE REPORT; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; LETTER; OLIGURIA; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BACTEREMIA; COMBINED MODALITY THERAPY; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MENINGOCOCCAL VACCINES; PLASMA EXCHANGE; PSEUDOMONAS INFECTIONS; RENAL DIALYSIS;

EID: 84904631277     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1972-1     Document Type: Letter

References (10)

1. Campistol JM, Arias M, Ariceta G et al (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: a consensus document. Nefrologia 33(1):27-45. doi:10.3265/Nefrologia.pre2012.Nov.11781
2. Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. NEJM 368:2169-2181. doi:10.1056/NEJMoa1208981
3. Laurence J (2012) Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol 10:1-12
4. Frimat M, Tabarin F, Dimitrov JD et al (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122(2):282 -292. doi:10.1182/blood-2013-03-489245
5. Ohanian M, Cable C, Halka K (2011) Reduced dose maintenance eculizumab in atypical uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 3:45-50. doi:10.2147/CPAA.S23687
6. Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759 - 767. doi:10.1016/S0140-6736(09)60001-5
7. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic uremic syndrome: case report. Transplant Proc 42:4353-4355. doi:10.1016/ j.transproceed. 2010.09. 125
8. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708-711. doi:10.1053/j.ajkd.2009.08.01
9. Prescott HC, Wu HM, Cataland SR, Baiocchi RA(2010) Eculizumab therapy in an adult with plasma-exchange refractory atypical hemolytic uremic syndrome. Am J Hematol 85:976-977. doi:10.1002/ajh.21862
10. Hillmen P, Muus P, Röth A et al (2013) Long-termsafety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162(1):62-73. doi:10.1111/bjh.12347